A further future perspective relates to a practical aspect occurring during glioma surgery: considering the increasing evidence on the positive relationship between the degree of surgical resection and extent of the survival in patients affected by gliomas harbouring IDH mutations (i.e., IDH-mutant gliomas patients have a better prognosis when the resection is total or even supra-total vs. the ones who undergo a sub-total/partial resection)23,39–41, the surgical approach could be tailored intra-operatively according to the IDH status findings. The gene discussed is IDH2; the disease is central nervous system cancer.